In the latest trading session, Advaxis (ADXS - Free Report) closed at $3.29, marking a -0.3% move from the previous day. This change lagged the S&P 500's 0.16% gain on the day. At the same time, the Dow added 0.42%, and the tech-heavy Nasdaq gained 0.03%.
Coming into today, shares of the biotechnology company had lost 54.38% in the past month. In that same time, the Medical sector lost 8.18%, while the S&P 500 gained 2.89%.
Investors will be hoping for strength from ADXS as it approaches its next earnings release. In that report, analysts expect ADXS to post earnings of -$1.49 per share. This would mark year-over-year growth of 63.03%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $0.77 million, down 56% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$2.40 per share and revenue of $21.72 million, which would represent changes of +87.53% and +258.16%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for ADXS. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 20% higher. ADXS is holding a Zacks Rank of #1 (Strong Buy) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 46, which puts it in the top 19% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
In the latest trading session, Advaxis (ADXS - Free Report) closed at $3.29, marking a -0.3% move from the previous day. This change lagged the S&P 500's 0.16% gain on the day. At the same time, the Dow added 0.42%, and the tech-heavy Nasdaq gained 0.03%.
Coming into today, shares of the biotechnology company had lost 54.38% in the past month. In that same time, the Medical sector lost 8.18%, while the S&P 500 gained 2.89%.
Investors will be hoping for strength from ADXS as it approaches its next earnings release. In that report, analysts expect ADXS to post earnings of -$1.49 per share. This would mark year-over-year growth of 63.03%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $0.77 million, down 56% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$2.40 per share and revenue of $21.72 million, which would represent changes of +87.53% and +258.16%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for ADXS. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 20% higher. ADXS is holding a Zacks Rank of #1 (Strong Buy) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 46, which puts it in the top 19% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on ADXS - FREE